Subscribe to Search results

At the meeting, Dr Kernoff stated Royal Free aimed to switch home treatment patients from cryoprecipitate to concentrate with currently (September 1978) still half of the home treatment patients still using cryoprecipitate which was deemed unacceptable.

Published on:

At the meeting, Dr Rankin commented their allocation had been reduced from 100 to 65 bottles of factor VIII due to shortage. This forced his reference centre to begin transferring patients to other Centres at a much younger age. Only half of their patients on home therapy could be treated with concentrate.

Published on:

Dr Kernoff suggested that cryoprecipitate, although relatively cheap to produce, had serious clinical disadvantages and that the shortfall in NHS concentrates had to be met by buying commercial concentrate.

Published on:

In his letter to Dr Colvin, Dr Kernoff described NANBH as a serious disease with long-term consequences.

Published on:

In his letter to Mr Jones, Dr Kernoff referred to the Royal Free policy to attempt to maintain individual patients on particular brands to minimise the risk of hepatitis.

Published on:

The NANBH risks associated with Factor 8 concentrates were the subject of discussion at the Haemophilia Working Party's meeting.

Published on:

At the meeting of the Haemophilia Working Party, it was agreed that all registered haemophiliacs on regular treatment should be fully screened for hepatitis at their regular three-month visits to the major haemophilia centres.

Published on:

Dr Kernoff stated 25% of all Factor VIII used was in the form of cryoprecipitate which was unsatisfactory at the Royal Free Hospital.

Published on:

A clinical study done by Dr Dormandy with the US counterparts demonstrated that haemophiliacs treated exclusively with the new concentrates suffered raised transaminases more commonly than UK patients who were treated with cryoprecipitate.

Published on:

In his oral evidence, Professor Howard Thomas agreed that he had given the Glasgow Symposium the message that there would be problems in the future with hepatitis, fibrosis and cirrhosis.

Published on:

Dr Kernoff agreed with Dr Dormany that factor concentrates exposed recipients to a greater risk of infection because of the large sizes of the pools from which they were made.

Published on:

Dr Craske published an article titled 'An outbreak of hepatitis associated with intravenous injection of Factor VIII concentrate' in The Lancet

Published on:

Dr Biggs served as director of the Oxford Reference Centre until 1977 when she was succeeded by Dr Rizza.

Published on:

Dr Biggs served as director until 1977 when she was succeeded by Dr Rizza.

Published on:

Due to the co-location and cooperation of the PFL and Oxford Haemophilia Centre, it made the switch from cryoprecipitate to factor concentrates relatively early.

Published on:

Between 1969 to 1974, cryoprecipitate use at the Oxford Haemophilia Centre dropped from 21.99% to 3.86% of total Factor 8 material used, while the use of NHS concentrate rose from 45.93% to 60.89% of the total.

Published on:

By 1975 there was only about 25% of Haemophilia A patients using home therapy.

Published on:

In 1977, Dr Bidwell said Factor 9 requirements had increased substantially. It did not allow for prophylactic treatment except for occasional short periods. But prophylaxis for severely affected patients was allowed where no substantial increase in usage occurred.

Published on:

By 1976, 42.6% of the material used at Oxford Haemophilia Centre was NHS Factor 8 concentrate, just 1.54% was cryoprecipitate, and the rest was commercial concentrate (Hyland & Immuno).

Published on:

Following an increase in plasma supplied, nearly double, the Oxford Centre was able to transfer several patients from commercial to NHS concentrate.

Published on: